BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 23863459)

  • 1. Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model.
    Rodino-Klapac LR; Janssen PM; Shontz KM; Canan B; Montgomery CL; Griffin D; Heller K; Schmelzer L; Handy C; Clark KR; Sahenk Z; Mendell JR; Kaspar BK
    Hum Mol Genet; 2013 Dec; 22(24):4929-37. PubMed ID: 23863459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy.
    Zhang Y; Yue Y; Li L; Hakim CH; Zhang K; Thomas GD; Duan D
    Hum Mol Genet; 2013 Sep; 22(18):3720-9. PubMed ID: 23681067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dystrophin restoration therapy improves both the reduced excitability and the force drop induced by lengthening contractions in dystrophic mdx skeletal muscle.
    Roy P; Rau F; Ochala J; Messéant J; Fraysse B; Lainé J; Agbulut O; Butler-Browne G; Furling D; Ferry A
    Skelet Muscle; 2016; 6():23. PubMed ID: 27441081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variable rescue of microtubule and physiological phenotypes in mdx muscle expressing different miniaturized dystrophins.
    Nelson DM; Lindsay A; Judge LM; Duan D; Chamberlain JS; Lowe DA; Ervasti JM
    Hum Mol Genet; 2018 Jun; 27(12):2090-2100. PubMed ID: 29618008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of α1-syntrophin and α-dystrobrevin in skeletal muscles of mdx mice.
    Koo T; Malerba A; Athanasopoulos T; Trollet C; Boldrin L; Ferry A; Popplewell L; Foster H; Foster K; Dickson G
    Hum Gene Ther; 2011 Nov; 22(11):1379-88. PubMed ID: 21453126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
    Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
    Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel adeno-associated viral vector delivering the utrophin gene regulator jazz counteracts dystrophic pathology in mdx mice.
    Strimpakos G; Corbi N; Pisani C; Di Certo MG; Onori A; Luvisetto S; Severini C; Gabanella F; Monaco L; Mattei E; Passananti C
    J Cell Physiol; 2014 Sep; 229(9):1283-91. PubMed ID: 24469912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AAV-mediated overexpression of human α7 integrin leads to histological and functional improvement in dystrophic mice.
    Heller KN; Montgomery CL; Janssen PM; Clark KR; Mendell JR; Rodino-Klapac LR
    Mol Ther; 2013 Mar; 21(3):520-5. PubMed ID: 23319059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lentiviral Micro-dystrophin Gene Treatment into Late-stage mdx Mice for Duchenne Muscular Dystrophy Disease.
    Eren SA; Tastan C; Karadeniz KB; Turan RD; Cakirsoy D; Kancagi DD; Yilmaz SU; Oztatlici M; Oztatlici H; Ozer S; Tumentemur G; Baykal AT; Ovali E
    Curr Gene Ther; 2023; 23(4):304-315. PubMed ID: 37032509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined effect of AAV-U7-induced dystrophin exon skipping and soluble activin Type IIB receptor in mdx mice.
    Hoogaars WM; Mouisel E; Pasternack A; Hulmi JJ; Relizani K; Schuelke M; Schirwis E; Garcia L; Ritvos O; Ferry A; 't Hoen PA; Amthor H
    Hum Gene Ther; 2012 Dec; 23(12):1269-79. PubMed ID: 22894762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice.
    Ebihara S; Guibinga GH; Gilbert R; Nalbantoglu J; Massie B; Karpati G; Petrof BJ
    Physiol Genomics; 2000 Sep; 3(3):133-44. PubMed ID: 11015608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isometric resistance training increases strength and alters histopathology of dystrophin-deficient mouse skeletal muscle.
    Lindsay A; Larson AA; Verma M; Ervasti JM; Lowe DA
    J Appl Physiol (1985); 2019 Feb; 126(2):363-375. PubMed ID: 30571283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Life-Long AAV-Mediated CRISPR Genome Editing in Dystrophic Heart Improves Cardiomyopathy without Causing Serious Lesions in mdx Mice.
    Xu L; Lau YS; Gao Y; Li H; Han R
    Mol Ther; 2019 Aug; 27(8):1407-1414. PubMed ID: 31129119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gene therapy for muscular dystrophy].
    Takeda S
    No To Hattatsu; 2004 Mar; 36(2):117-23. PubMed ID: 15031985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse.
    Godfrey C; Muses S; McClorey G; Wells KE; Coursindel T; Terry RL; Betts C; Hammond S; O'Donovan L; Hildyard J; El Andaloussi S; Gait MJ; Wood MJ; Wells DJ
    Hum Mol Genet; 2015 Aug; 24(15):4225-37. PubMed ID: 25935000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Truncated dystrophins reduce muscle stiffness in the extensor digitorum longus muscle of mdx mice.
    Hakim CH; Duan D
    J Appl Physiol (1985); 2013 Feb; 114(4):482-9. PubMed ID: 23221959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy.
    Harper SQ; Hauser MA; DelloRusso C; Duan D; Crawford RW; Phelps SF; Harper HA; Robinson AS; Engelhardt JF; Brooks SV; Chamberlain JS
    Nat Med; 2002 Mar; 8(3):253-61. PubMed ID: 11875496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models.
    Song Y; Morales L; Malik AS; Mead AF; Greer CD; Mitchell MA; Petrov MT; Su LT; Choi ME; Rosenblum ST; Lu X; VanBelzen DJ; Krishnankutty RK; Balzer FJ; Loro E; French R; Propert KJ; Zhou S; Kozyak BW; Nghiem PP; Khurana TS; Kornegay JN; Stedman HH
    Nat Med; 2019 Oct; 25(10):1505-1511. PubMed ID: 31591596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.